IUC26678-94

Abstract Code: IUC26678-94   Impact of Metastatic Patterns on First-Line Therapy in mRCC: Meet-URO 33 E. Peretto 1, S.E. Rebuzzi 2, E. Verzoni 3, S. Buti 4, M. Di Napoli 5, C. Lolli 6, M. Fanelli 7, C. Masini 8, P.A. Zucali 9, A. Mennitto 10, M. Sorarù 11, R....

IUC26672-88

Abstract Code: IUC26672-88   Treatment beyond progression in primary refractory mRCC during 1L systemic therapy (Meet-Uro 33) D. Aspden 1, D. Bimbatti 2, A. Dalla Volta 3, G. Roviello 4, R. Iacovelli 5, G. Bozza 6, M.G. Vitale 7, E. Fantinel 8, A. Guida 9, F.M....

IUC26671-87

Abstract Code: IUC26671-87   Adjuvant Pembrolizumab in RCC: Real world experience in Northern Ireland 2022-2026 S. Buchanan 1, G. Clements 1, C. Forde 1, A. Clayton 1 (1) Northern Ireland cancer centre, Belfast – United Kingdom   Objective: Adjuvant...

IUC26666-91

Abstract Code: IUC26666-91   Prediction of immune-related adverse events (irAEs) with hematologic markers in patients receiving first-line immune checkpoint inhibitor (ICI)-based therapy in metastatic renal cell carcinoma (mRCC) R. Winayak 1, X. Li 1, N.J. Salgia...

IUC26658-92

Abstract Code: IUC26658-92   Efficacy Patterns of First-Line Immune Checkpoint Inhibitor Combinations in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis Evaluating Ethnic Variations D. Khanna 1, T. Dey 2, E. Blanchard-Cavagis 3,...
error: Content is protected !!